Glenmark Life Sciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
January 23, 2024 at 05:20 pm IST
Share
Glenmark Life Sciences Limited reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported sales was INR 5,728.04 million compared to INR 5,407.31 million a year ago. Revenue was INR 5,744.95 million compared to INR 5,473.39 million a year ago. Net income was INR 1,187.65 million compared to INR 1,049.93 million a year ago. Basic earnings per share from continuing operations was INR 9.69 compared to INR 8.57 a year ago. Diluted earnings per share from continuing operations was INR 9.67 compared to INR 8.57 a year ago.
For the nine months, sales was INR 17,466.17 million compared to INR 15,399 million a year ago. Revenue was INR 17,555.28 million compared to INR 15,660.21 million a year ago. Net income was INR 3,729.52 million compared to INR 3,206.04 million a year ago. Basic earnings per share from continuing operations was INR 30.44 compared to INR 26.16 a year ago. Diluted earnings per share from continuing operations was INR 30.42 compared to INR 26.16 a year ago.
Glenmark Life Sciences Limited is an India-based company that is primarily engaged in the business of development, manufacture and marketing of active pharmaceutical ingredients (API). The Companyâs product portfolio comprises of various therapeutic segments, which include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, gastrointestinal health, oncology, pain management and anti-infectives. Its products include Adapalene, Alogliptin Benzoate, Amiodarone HCl, Esomeprazole Sodium, Eszopiclone, Etoricoxib, Omeprazole, Oxcarbazepine, Zolpidem Tartrate, Zonisamide and Voriconazole. The Companyâs products also include Vildagliptin, Aprepitant, Bosentan, Cilostazol, Deferasirox, Fluconazole, Ivacaftor, Pirfenidone, Riluzole, Sucralfate, Ticagrelor, Telmisartan and Umifenovir. The Companyâs research and development facilities are located at Mahape, Ankleshwar and Dahej in India and manufacturing facilities are located at Ankleshwar, Dahej, Mohol and Kurkumbh.